Publichealth.arizona.edu

CURRICULUM VITAE
CHENGCHENG HU
Mel and Enid Zuckerman College of Public Health 1295 N. Martin A228Campus P. O. Box 245211Tucson, AZ 85724 CHRONOLOGY OF EDUCATION
Ph.D. in Biostatistics, University of Washington, Seattle, WA Dissertation: Semiparametric failure-time regression with mismeasured M.S. in Biostatistics, University of Washington, Seattle, WA M.A. in Mathematics, Johns Hopkins University, Baltimore, MD Undergraduate Study in Mathematics, Peking University, Beijing, China CHRONOLOGY OF EMPLOYMENT
Academic Positions
Assistant Professor, Public Health, Division of Epidemiology andBiostatistics, Mel and Enid Zuckerman College of Public Health,University of Arizona, Tucson, AZ Member, Graduate Interdisciplinary Program in Statistics,University of Arizona, Tucson, AZ Member, BIO5 Institute, University of Arizona, Tucson, AZ Assistant Professor of Biostatistics, Department of Biostatistics,Harvard School of Public Health, Boston, MA Senior Statistician, Center for Biostatistics in AIDS Research,Harvard School of Public Health, Boston, MA Postdoctoral Research Fellow, Department of Biostatistics,Harvard School of Public Health, Boston, MA Research Assistant, Fred Hutchinson Cancer Research Center,Seattle, WA Teaching Assistant, Department of Biostatistics,University of Washington, Seattle, WA Teaching Assistant, Department of Mathematics,Johns Hopkins University, Baltimore, MD Other Experience
Consultant, Center for Biostatistics in AIDS Research,Harvard School of Public Health, Boston, MA Intern and Visiting Scientist, Genentech, Inc.,South San Francisco, CA HONORS AND AWARDS
Best Written Paper, Student Paper CompetitionInternational Biometric Society (WNAR) Donovan J. Thompson Award for Academic Excellence in Biostatistics,University of Washington, Seattle, WA Tuition Fellowship, Johns Hopkins University, Baltimore, MD Finalist and Third-Prize Winner, Chinese Mathematics Olympiad SERVICE/OUTREACH
External Service
Member, Adolescent Research Agenda Committee, Pediatric AIDS Clinical Trials Member, NIH/NCI Small Grants for Cancer Epidemiology (R03) Review Panel, April, 2009; June, 2009; October, 2009; April, 2010; June, 2010.
Reviewer, James and Esther King Biomedical Research Program administered by the Florida Department of Health, February, 2010.
Member, Program Faculty, Sequencing the Genome: Implications for Cancer Therapy, A Primer for the Practicing Physician, Phoenix, AZ, February, 2011.
Reviewer, Bankhead-Coley Cancer Research Program, Florida Department of Reviewer, Bankhead-Coley Cancer Research Program, Florida Department of Professional Societies
Referee Service
Bioinformatics, Biometrics (4 articles), Circulation, Journal of Sta-tistical Planning and Inference, Journal of the American StatisticalAssociation (4 articles), Lifetime Data Analysis (2 articles), PatternRecognition Letters, Scandinavian Journal of Statistics, StatisticaSinica, Statistical Applications in Genetics and Molecular Biology,and Statistics & Probability Letters Canadian Journal of Statistics, Circulation (2 articles), Circulation:Arrhythmia and Electrophysiology, and Circulation: Cardiovascu-lar Interventions Circulation (3 articles), Circulation: Arrhythmia and Electrophysi-ology, Circulation: Cardiovascular Imaging, and The Oncologist Circulation (3 articles), Circulation: Cardiovascular Interventions,and Contemporary Clinical Trials (3 articles).
Internal Service
Colloquium Committee, Dept. of Biostatistics, 2002-2004, 2005-2007.
Curriculum Committee, Dept. of Biostatistics, 2002-2003, 2007-2008.
Postdoctoral Committee, Dept. of Biostatistics, 2002-2003, 2004-2005, 2006- Hiring Committee, Center for Biostatistics in AIDS Research, 2003-2006.
Newsletter Committee, Dept. of Biostatistics, 2003-2004.
Qualifying Exam Committee, Dept. of Biostatistics, 2003-2004.
Teaching Effectiveness Committee, Dept. of Biostatistics, 2003-2005.
Diversity Committee, Dept. of Biostatistics, 2004-2005.
Webpage Committee, Dept. of Biostatistics, 2005-2008.
Admission and Recruiting Committee, Dept. of Biostatistics, 2006-2007.
Colloquia & Forums Committee (Chair), Graduate Interdisciplinary Program in Research Advisory Committee, Mel and Enid Zuckerman College of Public Health, Biostatistics Admissions, Division of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, 2009-present Website Workgroup, Division of Epidemiology and Biostatistics, Mel and Enid Peer Review Committee, Division of Epidemiology and Biostatistics, Mel and Enid Biostatistics Search Committee, Division of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, 2011-present Executive Committee, Graduate Interdisciplinary Program in Statistics, 2011-present Curriculum Committee (Chair), Graduate Interdisciplinary Program in Statistics, PUBLICATIONS/CREATIVE ACTIVITY
Peer-Reviewed Publications
1. Etzioni RD, Feuer EJ, Sullivan SD, Lin DY, Hu C, and Ramsey SD (1999). On
the use of survival analysis techniques to estimate medical care cost. Journalof Health Economics 18(3), 365–80.
2. Etzioni RD, Pepe MS, Longton G, Hu C, and Goodman GE (1999). Incorpo-
rating the time dimension in receiver operating characteristic curves: a casestudy of prostate cancer. Medical Decision Making 19(3), 242-51.
3. Ellis WJ, Etzioni RD, Vessella RL, Hu C, and Goodman GE (2001). Serial
prostate specific antigen, free-to-total prostate specific antigen ratio and com-plexed prostate specific antigen for the diagnosis of prostate cancer. Journalof Urology 166(1), 93-8; discussion 98-9.
4. *Hu C and Lin DY (2002). Cox regression with covariate measurement error.
Scandinavian Journal of Statistics 29(4), 637-655.
5. Huang X, Wolfe RA, and Hu C (2004). A test for informative censoring in
clustered survival data. Statistics in Medicine 23(13), 2089-2107.
6. *Hu C and Lin DY (2004). Semiparametric failure time regression with repli-
cates of mismeasured covariates. Journal of the American Statistical Asso-ciation 99, 105-118.
7. Liu J, Sukhova GK, Yang JT, Sun J, Ma L, Ren A, Xu WH, Fu H, Dolganov GM, Hu C, Libby P, and Shi GP (2006). Cathepsin L expression and regulation
in human abdominal aortic aneurysm, atherosclerosis, and vascular cells.
Atherosclerosis 184, 302-311.
8. Liu J, Ma L, Yang J, Ren A, Sun Z, Yan G, Sun J, Fu H, Xu W, Hu C, and
Shi GP (2006). Increased serum cathepsin S in patients with atherosclerosisand diabetes. Atherosclerosis 186, 411-419.
9. Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD, and the PACTG P1026S
Study Team (2006). Impact of pregnancy on abacavir pharmacokinetics.
AIDS 20, 553-560.
10. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C,
Holland DT, Smith E, Tuomala R, Cotter A, Read JS, for the PACTG 1026SStudy Team (2006). Reduced lopinavir exposure during pregnancy. AIDS 20,1931-1939.
11. Wang KH, Majewska A, Schummers J, Farley B, Hu C, Sur M, and Tonegawa
S (2006). In vivo two-photon imaging reveals a role of Arc in enhancingorientation specificity in visual cortex. Cell 126, 389-402.
12. Chen YQ, Hu C, and Wang Y (2006). Attributable risk function in the propor-
tional hazards model for censored time-to-event. Biostatistics 7, 515-529.
13. Hars ES, Qi H, Ryazanov AG, Jin S, Cai L, Hu C, and Liu LF (2007). Au-
tophagy regulates ageing in C. elegans. Autophagy 3, 93-95.
14. Hu C and De Gruttola V (2007). Joint modeling of progression of HIV re-
sistance mutations measured with uncertainty and time to virological failure.
Biometrics 63, 60-68.
15. Fiscus SA, Kovacs A, Petch LA, Hu C, Wiznia AA, Mofenson LM, Yogev R,
McIntosh K, Pelton SI, Napravnik S, Stanley KE, and Nachman SA (2007).
Baseline resistance to nucleoside reverse transcriptase inhibitors fails to pre-dict virologic response to combination therapy in children (PACTG 338). AIDSResearch and Therapy, 2007; 4:2.
16. McKinney RE, Rodman J, Hu C, Britto P, Hughes M, Smith ME, Serchuk LK,
Kraimer J, Ortiz AA, Flynn P, Yogev R, Spector S, Draper L, Tran P, Scites M,Dickover R, Weinberg A, Cunningham C, Abrams E, Blum HR, Chittick GE,Reynolds L, Rathore M, and Pediatric AIDS Clinical Trials Group ProtocolP1021 Study Team (2007). Long term safety and efficacy of a once-dailyregimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents (Pediatric AIDS Clinical Trials Group protocolP1021). Pediatrics, 2007; 120, e416-e423.
17. Healy BC, De Gruttola VG, and Hu C (2008). Accommodating uncertainty
in tree set for function estimation. Statistical Applications in Genetics andMolecular Biology, 7, Iss. 1, Article 5.
Available at: http://www.bepress.com/sagmb/vol7/iss1/art5 18. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E,
Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, ShearerWT, Foca M, Mirochnick M, for the PACTG 1026S and P1022 Study Teams(2008). Chronic administration of nevirapine during pregnancy: impact ofpregnancy on pharmacokinetics. HIV Medicine 9(4), 214-220.
19. Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett
SK, Smith ME, Sheeran BC, Shearer WT, Febo I, and Mirochnick M (2008).
Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy andpostpartum. HIV Medicine, 9(10), 875-882.
20. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland
DT, Smith E, Gaddipati S, Read JS, for the PACTG 1026S Study Team (2008).
Lopinavir exposure with an increased dose during pregnancy. Journal ofAcquired Immune Deficiency Syndromes, 49(5), 485-491.
21. Weinberg A, Dickover R, Britto P, Hu C, Patterson-Bartlett J, Kraymer J, Gutz-
man H, Shearer W, Gelman R, Rathore M, McKinney R, and the PACTG 1021Team (2008). Continuous improvement in the immune system of HIV-infectedchildren on prolonged antiretroviral therapy. AIDS, 22(17), 2267-2277.
22. Garvie PA, Cremeens J, Gaur AH, Flynn PM, Belzer M, McSherry G, and Hu C for the Pediatric AIDS Clinical Trials Group 1036A Study Team (2009).
Development of a directly observed therapy adherence intervention for ado-
lescents with Human Immunodeficiency Virus-1: application of focus group
methodology to inform design, feasibility and acceptability. Journal of Ado-
lescent Health, 44(2), 124-132.
23. Aweeka FT, Stek A, Best B, Hu C, Holland D, Hermes A, Burchette SK, Read
J, Mirochnick M, Capparelli EV, and the International Maternal Pediatric Ado-lescent AIDS Clinical Trials Group (IMPAACT) P1026s Protocol Team (2010).
Lopinavir protein binding in HIV-1 infected pregnant women. HIV Medicine,11, 232-238.
24. Stratton SP, Alberts DS, Einspahr JG, Sagerman PM, Warneke JA, Curiel CN, Myrdal PB, Karlage K, Nickoloff B, Brooks C, Saboda K, Yozwiak M,
Krutzsch MR, Hu C, Lluria-Prevatt M, Dong Z, Bowden GT, Bartels PH (2010).
A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin
cancer. Cancer Prevention Research, 3(2), 160-169.
25. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E,
Read JS, Capparelli EV for the IMPAACT 1026 Study Team (2010). Lopinavirtablet pharmacokinetics with an increased dose during pregnancy. Journalof Acquired Immune Deficiency Syndromes, 54(4), 381-388.
26. Gaur AH, Belzer M, Britto P, Garvie PA, Hu C, Graham B, Neely M, Mc-
Sherry G, Spector SA, and Flynn PM for the Pediatric AIDS Clinical TrialsGroup P1036B Team (2010). Directly observed therapy (DOT) for nonadher-ent HIV-infected youth: lessons learned, challenges ahead. AIDS Researchand Human Retroviruses, 26(9), 947-953.
27. Hibler EA, Jurutka PW, Egan JB, Hu C, LeRoy EC, Mart´ınez ME, Thompson
PA, Jacobs ET (2010). Association between polymorphic variation in VDRand RXRA and circulating levels of vitamin D metabolites. Journal of SteroidBiochemistry and Molecular Biology, 121, 438-441.
28. Nasser FS, Ritsema DF, Cheney S, Stern K, Sokoloff MH, Hu C, Nguyen MM
(2010). Reviewing radiographic images with patients: a trial on patient pref-erences, understanding, and satisfaction. Journal of Endourology, 24(12),2083-91.
29. McKenzie NE, Saboda K, Duckett LD, Goldman R, Hu C, and Curiel-Lewandrowski
CN (2011). Development of a photographic scale for consistency and guid-ance in dermatological assessment of forearm sun damage. Archives of Der-matology, 147(1), 31-36.
30. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Rossi
SS, Hawkins E, Basar M, Smith E, Read JS for the IMPAACT P1026s StudyTeam (2011). Atazanavir pharmacokinetics with and without tenofovir duringpregnancy. Journal of Acquired Immune Deficiency Syndromes, 56(5), 412-419.
31. Dickinson SE, Olson ER, Zhang J, Cooper SJ, Melton T, Criswell PJ, Casanova A, Dong Z, Hu C, Saboda K, Jacobs ET, Alberts DS, and Bowden GT (2011).
p38 MAP kinase plays a functional role in UVB-induced mouse skin carcino-
genesis. Molecular Carcinogenesis, 50, 469-478.
32. Bea JW, Wright NC, Thompson P, Hu C, Guerra S, and Chen Z (2011). Per-
formance evaluation of a multiplex assay for future use in biomarker discov-ery efforts to predict body composition. Clinical Chemistry and LaboratoryMedicine, 49(5), 817-824.
33. LeRoy EC, Moore JH, Hu C, Mart´ınez ME, Lance P, Duggan D, Thompson PA
(2011). Genes in the insulin and insulin-like growth factor pathway and oddsof metachronous colorectal neoplasia. Human Genetics, 129(5), 503-512.
34. Garvie PA, Flynn PM, Belzer M, Britto P, Hu C, Graham B, Neely M, Mc-
Sherry GD, Spector SA, and Gaur AH for the Pediatric AIDS Clinical TrialsGroup (PACTG) P1036B Team (2010). Psychological factors, beliefs aboutmedication, and adherence of youth with HIV-1 in a multisite directly observedtherapy (DOT) pilot study. Journal of Adolescent Health, 48(6), 637-640.
35. Hu C and De Gruttola V (2011). Recursive partitioning of resistant mutations
for longitudinal markers based on a U-type score. Biostatistics, 12(4), 750-762.
36. Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, Li H, Read JS,
Jennings A, Barr E, Smith E, Rossi SS, and Mirochnick M. (2011). Antepar-tum and postpartum pharmacokinetics of emtricitabine. HIV Medicine, ac-cepted.
37. Hibler EA, Hu C, Jurutka PW, Mart´ınez ME, and Jacobs ET (2011). Polymor-
phic variation in GC and CASR and associations with Vitamin D metaboliteconcentration and metachronous colorectal neoplasia. Cancer epidemiology,biomarkers & prevention, accepted.
Book Chapter
1. Wang W and Hu C (2006). Proportional hazards regression models. Springer
Handbook of Engineering Statistics (Pham H, editor), 387-395. New York:Springer-Verlag, Inc.
Other Publication
1. *Hu C and Lin DY (2000). Corrected imputation method for Cox regression
with missing covariates. Proceedings of the American Statistical Association,Biometrics Section, 2000.
Manuscripts Submitted or Under Revision
1. Spivak-Kroizman T, Hostetter G, Posner R, Aziz M, Hu C, Demeure M, Von
Hoff D, Hingorani S, Palculict TB, Kiriakova GM, Abdelmelek M, BartholomeuszG, James BP, and Powis G (2012). Hypoxia mediates a novel tumor-stromainteraction through Hedgehog signaling in pancreatic cancer. Submitted.
2. Diep CH, Zucker KM, Hostetter G, Watanabe A, Hu C, Von Hoff DD, and Han
H (2012). Down-regulation of Yes Associated Protein 1 expression reducescell proliferation and clonogenicity of pancreatic cancer cells. Submitted.
3. Olson ER, Henricksen LA, Luecke L, Chafin DR, Rajagopalan N, Rodr´ıguez JJ, Boswell CA, Elliott DA, Hu C, Einspahr JG, Alberts DS, Bowden GT,
and Dixon K (2012). Phosphorylation of replication protein A is a detectable
biomarker for UVB-induced DNA damage in skin. Submitted.
4. Burgess JL, Duncan M, Hu C, Littau S, Caseman D, Spencer MK, Davis-
Gorman G, McDonagh PF (2012). Acute cardiovascular effects of firefightingand active cooling during rehabilitation.effects. Submitted.
Work in Progress
1. Hu C and De Gruttola V (2012). A U-statistic based random forest approach
for longitudinal markers and haplotypes.
2. Hu C and De Gruttola V (2012). Time-varying trees for longitudinal genetic
3. Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchette SK, Read
J, Mirochnick M, Capparelli EV, and the International Maternal Pediatric Ado-lescent AIDS Clinical Trials Group (IMPAACT) P1026S Protocol Team (2012).
Alteration in cytochrome P450 3A4 activity in HIV-1 infected pregnant womenand relationship to antiretroviral pharmacokinetics.
4. Silio M, Sirois PA, Hu C, Britto P, Flynn PM, Goodenow MM, Sleasman JW,
Fletcher C, Ferguson E, Van Dyke R, and the P1034 Study Team (2012).
Evaluation of Adherence Measures in Adolescents with HIV.
Peer-Reviewed Abstracts
1. McKinney R, Rathore M, Jankelovich S, Mofenson L, Wang L, Reynolds L, Hughes M, Hu C, Draper L, Buckley E, Purdue L, Ortiz A, Dickover R, Wein-
berg A, Rodman J (2003). PACTG 1021: an ongoing phase I/II study of
once-daily emtricabine, didanosine, and efavirenz in therapy-naive or mini-
mally treated pediatric patients. The 10th Conference on Retroviruses and
Opportunistic Infections, Boston, MA.
2. McKinney R, Rodman J, Rathore M, Hu C, Flynn P, Hughes M, Dickover
R, Weinberg A, Blum MR, Sahner D, Jankelevich S, Serchuck L, Ortiz B,Tran P, and Pediatric AIDS Clinical Trials Group (2004). Extended follow-upand pharmacokinetics for once daily emtricitabine, didanosine, and efavirenzfor antiretroviral nave children and adolescents. The 11th Conference onRetroviruses and Opportunistic Infections, San Francisco, CA.
3. Stek A, Mirochnick M, Capparelli E, Best B, Burchett SK, Hu C, Gardella J,
Elgie C, Schiffhauer J, Smith E, Read J, and Tuomala R (2004). Reducedlopinavir exposure during pregnancy: preliminary pharmacokinetic resultsfrom pactg 1026. The 15th International AIDS Conference, Bangkok, Thai-land.
4. Best B, Capparelli EV, Stek A, Burchett S, Read J, Smith E, Hu C, Gardella J,
Elgie C, Schiffhauer J, Mirochnick M, and PACTG 1026S Study Team (2004).
Abacavir pharmacokinetics during pregnancy. Journal of clinical pharmacol-ogy. 44 (10), 1199.
5. Capparelli E, Aweeka F, Best B, Hu C, Hitti J, Frenkel L, Stek A, and Mirochnick
M (2005). Effect of pregnancy on nevirapine pharmacokinetics during chronictherapy. The 6th International Workshop on Clinical Pharmacology of HIVTherapy, Qubec City, Quebec, Canada.
6. McKinney R, Rathore M, Hu C, Britto P, Smith M, Serchuck L, Rodman J,
Draper L, Reynolds L, Chittick G, and Pediatric ACTG Protocol 1021 Team(2006). Phase I/II study of a once-daily regimen of emtricitabine, didano-sine, and efavirenz in HIV-infected, therapy-nave children and adolescents:PACTG Protocol 1021. The 13th Conference on Retroviruses and Oppor-tunistic Infections, Denver, CO.
7. Dickover R, Smith D, Britto P, Hu C, Weinberg A, Rathore M, McKinney R,
and the P1021 Study Team (2006). TREC Response in P1021: A once-daily regimen of emtricitabine, didanosine, and efavirenz in previously naivechildren. The 13th Conference on Retroviruses and Opportunistic Infections,Denver, CO.
8. Weinberg A, Britto P, Hu C, Dickover R, Rathore M, McKinney R, and PACTG
Team P1021 (2006). Virologic and immunologic correlates of immune recon-stitution in HIV-infected children on FTC/DDI/EFV: PACTG Protocol P1021.
The 13th Conference on Retroviruses and Opportunistic Infections, Denver,CO.
9. Mirochnick M, Stek A, Capparelli E, Best B, Holland D, Connor J, Burchett S, Hu C, Smith E, Read J, and PACTG 1026S Protocol Team (2006). Adequate
lopinavir exposure achieved with a higher dose during the third trimester of
pregnancy. The 13th Conference on Retroviruses and Opportunistic Infec-
tions, Denver, CO.
10. Weinberg A, Britto P, Hu C, Dickover R, Patterson J, Smith D, Gutzman H,
Kraimer J, Rathore M, McKinney M, and PACTG P1021 Team (2007). De-layed recovery of HIV-specific CD4-mediated immunity in HIV-Infected Chil-dren on their first HAART regimen (PACTG P1021). The 14th Conference onRetroviruses and Opportunistic Infections, Los Angeles, CA.
11. Read JS, Best B, Stek A, Hu C, Capparelli E, Holland D, Burchett SK, Smith
E, Sheeran B, and Mirochnick M (2007). Nelfinavir pharmacokinetics (625-mg tablets) during the third trimester of pregnancy and post-partum. The14th Conference on Retroviruses and Opportunistic Infections, Los Angeles,CA.
12. Aweeka FT, Stek A, Best B, Hu C, Holland D, Hermes A, Burchett S, Read
J, Mirochnick M, and Capparelli EV. (2007). Lopinavir protein binding duringpregnancy. The 14th Conference on Retroviruses and Opportunistic Infec-tions, Los Angeles, CA.
13. Burchett S, Best B, Mirochnick M, Hu C, Capparelli E, Holland D, Smith E,
Sheeran B, Read J, Stek A, and PACTG P1026S Team (2007). Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. The 14thConference on Retroviruses and Opportunistic Infections, Los Angeles, CA.
14. Rathore M, McKinney R, Hu C, Britto P, Smith M, Serchuck L, Draper L,
Reynolds L, Chittick G, Weinberg A, and the PACTG 1021 Protocol Team(2008). PACTG protocol 1021: a phase I/II study of a once-daily regimenof emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-nave chil-dren and adolescents. The 15th Conference on Retroviruses and Oppor-tunistic Infections, Boston, MA.
15. Best BM, Stek A, Hu C, Burchett SK, Rossi SS, Smith E, Sheeran B, Read
JS, Capparelli EV, and Mirochnick M for the PACTG/IMPAACT P1026S Team(2008). High-dose lopinavir and standard-dose emtricitabine pharmacokinet-ics during pregnancy and postpartum. The 15th Conference on Retrovirusesand Opportunistic Infections, Boston, MA.
16. Gaur A, Belzer M, Britto P, Garvie P, Hu C, Graham B, Klingman K, Neely
M, McSherry G, and Flynn P for the Pediatric AIDS Clinical Trials GroupP1036B Team (2008). Directly observed therapy for non-adherent HIV in-fected adolescents - lessons learned, challenges ahead. The 15th Confer-ence on Retroviruses and Opportunistic Infections, Boston, MA.
17. Garvie PA, Flynn PM, Britto P, Belzer M, Hu C, Graham B, Klingman K, Neely
M, McSherry GD, and Gaur AH for the Pediatric AIDS Clinical Trials GroupP1036B Team (2008). Psychological factors, beliefs about medicine, and ad-herence of youth with HIV-1 in a directly observed therapy (DOT) pilot study.
The 3rd International Conference on HIV Treatment Adherence, Jersey City,NJ.
18. Capparelli E, Rochon-Duck M, Robbins B, Rathore M, Britto P, Hu C, Wein-
berg A, Browning R, Hazra R, McKinney R, and IMPAACT P1021 Study Team(2009). Age-related Pharmacokinetics of Efavirenz Solution. The 16th Con-ference on Retroviruses and Opportunistic Infections, Montral, Canada.
19. Mirochnick M, Stek A, Capparelli E, Best B, Rossi S, Burchett S, Hu C,
Sheeran E, Smith E, Read J, and PACTG 1026s Protocol Team (2009). AtazanavirPharmacokinetics with and without Tenofovir during Pregnancy. The 16thConference on Retroviruses and Opportunistic Infections, Montral, Canada.
20. Curiel-Lewandrowski C, LaPresto L, Hu C, Saboda K, Krutszch M, Nagle
R, and Einsphar J (2011). Correlation between VEGF-A, VEGFR-1, pAkT,and pErk expression in melanocytic lesions and degree of histological atypia.
Journal of Investigative Dermatology, 131, S128.
21. Whatcott CJ, Jiang P, Watanabe A, Hostetter G, Hu C, Shepard M, Frost G,
Von Hoff D, and Han H (2011). Hyaluronan deposition correlates with poorsurvival in pancreatic cancer. AACR 102nd Annual Meeting, Orlando, FL.
22. Hibler EA, Hu C, Jurutka PW, Mart´ınez ME, Wagoner CL, and Jacobs ET
(2011). Effect of over-the-counter vitamin D supplementation on circulating25-hydroxyvitamin D concentration. Cancer Prevention Research 2011; 4(10Suppl):B103.
SCHOLARLY PRESENTATIONS
Conference Presentations
Hu C and Lin DY: Cox regression with covariate measurement error, 1999 Inter-
national Biometric Society (WNAR) Meeting, Seattle, WA (contributed).
Hu C and Lin DY: Cox regression with covariate measurement error, International
Biometric Conference 2000, Berkeley, CA (contributed).
Hu C and Lin DY: Corrected imputation method for Cox regression, 2000 Joint
Statistical Meetings, Indianapolis, IN (contributed).
Hu C and Lin DY: Analysis of recurrent event data with covariate measurement
error, 2002 International Biometric Society (ENAR) Meeting, Crystal City, VA(contributed).
Hu C and De Gruttola V: Joint modeling of interval censored HIV mutations and
failure time data, 2008 International Biometric Society (ENAR) Meeting, Crys-tal City, VA (invited).
Hu C and De Gruttola V: A U-statistic based random forest approach for longitudi-
nal markers, 2011 Joint Statistical Meetings, Miami Beach, FL (contributed).
Invited Colloquia and Seminars
Cox regression with covariate measurement error, Genentech, Inc., South San Cox-type regression with covariate measurement error, St. Jude Children’s Re- Cox regression with mismeasured or missing covariates, Department of Statistics, North Carolina State University, 2001; Department of Statistics, Universityof Illinois at Urbana-Champaign, 2001; Division of Biostatistics, Ohio StateUniversity, 2001; Department of Biostatistics, University of Michigan, 2001;Department of Statistics, Florida State University, 2001; Department of Bio-statistics, Harvard School of Public Health, 2001; Department of Biostatistics,University of North Carolina, 2001; Division of Biostatistics, Indiana Univer-sity, 2001; Division of Biostatistics, University of Texas, 2001; Department ofBiostatistics, Boston University, 2001; Department of Oncology, Johns Hop-kins University, 2001; Department of Epidemiology and Biostatistics, Univer-sity of California, San Francisco, 2001.
Joint modeling of HIV resistance mutations and failure time data, Division of Bio- statistics, Yale School of Public Health, New Haven, CT, 2004.
Joint modeling of progression of HIV resistance mutations measured with uncer- tainty and failure time data, Department of Statistics, University of Missouri,Columbia, MO, 2006.
Recursive partitioning methods in the study of HIV resistance mutations, Mas- sachusetts General Hospital, Boston, MA, 2007; Children’s Hospital Boston,Boston, MA, 2008; University of Arizona Mel and Enid Zuckerman College ofPublic Health, 2008.
Recursive partitioning in the analysis of longitudinal markers, Arizona Cancer Time-varying trees in the study of HIV resistance mutations, University of Arizona Mel and Enid Zuckerman College of Public Health, Tucson, AZ, 2011.
A random forest approach for longitudinal markers and unobserved haplotypes, University of Arizona Mel and Enid Zuckerman College of Public Health, Tuc-son, AZ, 2012.
Current Grants (funding amount is for most recent year if not indicated otherwise)
NIH/NCI P01CA027502 (PI: Alberts), 7/1/11 – 6/30/16, $942,451Chemoprevention of Skin Cancer Program ProjectRole: Director of Biometry Core (15% FTE)The Biometry Core provides statistical and data management support to all projectsand other cores of this grant, and as a unique expertise provides support to clinical trials involving karyometric endpoints. As the core director I oversee all aspectsof this core, integrate core activities with the grant objectives, participate in studydesign and monitoring, lead all data analysis efforts, and co-author manuscripts.
In addition, I develop new statistical methods for the analysis of karyometric data.
NIH/NCI P30CA23074 (PI: Alberts), 7/1/09 – 6/30/14, $235,264Arizona Cancer Center Support GrantRole: Co-Investigator (2% FTE)My work is to provide statistical support for research at the Arizona Cancer Center.
NIH/NCI 5U01 CA128454 (PI: Cunningham), 7/1/09 - 6/30/11, $65,596Tumor Glycomics Laboratory for Pancreatic CarcinomaRole: Co-Investigator (2% FTE)My work is to provide statistical expertise for the analysis of newly developedglycomic biomarkers.
CDC/NIOSH 1R01OH009469 (PI: Burgess), 9/1/09 – 8/31/13, $337,026Implementing Risk Management Strategies To Prevent Injuries Among Firefight-ersRole: Co-Investigator (10% FTE)My work is to provide statistical expertise for all aspects of this grant.
FEMA AFG (PI: Burgess), 4/23/10 – 4/22/13, $1,000,000 (3-year)Firefighter Statin TrialRole: Co-Investigator (10% FTE)My work is to provide statistical expertise for the design, conduct, and data anal-ysis of this clinical trial.
NIH/NCI 1U01CA153086-01 (PIs: Mart´ınez and Futscher), 9/17/10 – 8/31/15,$321,936Epigenetic Features of Pregnancy-Associated Breast Cancer in Hispanic WomenRole: Co-Investigator (5% FTE)My work is to provide statistical expertise for all aspects of this grant.
NIH/NIAMS R21AR060811 (PI: Chen), 10/1/11 – 9/30/13A New Hip Fracture Risk Prediction Tool Based on Common Predictors and HipGeometryRole: Co-InvestigatorMy work is to provide statistical expertise for this grant.
Completed Grants
NIH/NIAID R01AI051164 (PI: De Gruttola; Subcontract PI: Hu), 7/1/09 – 11/30/11,$56,591Methods for Long-Term Follow-Up of HIV-Infected PatientsRole: Principal Investigator of University of Arizona subcontract (25 ∼ 30% FTE)My work is to develop novel high-dimensional statistical methods to investigatethe relationship between high dimensional genetic and genomic information withclinical outcomes.
NIH/NCI P01CA027502 (PI: Alberts), 10/1/08 – 12/31/10, $750,000Chemoprevention of Skin Cancer Program ProjectRole: Director of Biometry Core (17% FTE before 2/1/10; 0% FTE during thebridging period 2/1/10 – 12/31/10)As the core director I oversaw all aspects of this core, integrated core activitieswith the grant objectives, participated in study design and monitoring, lead all dataanalysis efforts, and co-authored manuscripts.
NIH/NCI P01CA109552 (PI: Von Hoff), 7/1/09 – 8/31/10, $65,000Targets to Therapeutics in Pancreatic CancerRole: Co-Director of Pattern Analysis and Computational Biology Core (8 ∼ 12%FTE)As a co-director of this core I oversaw all statistical activities of this grant, partici-pated in study design, conducted data analysis, and co-authored manuscripts.
CDC/NIOSH 200-2008-24858 (PI: Burgess), 1/1/09 – 11/1/09, $12,600Development of a Severe Injury Surveillance System for Hazard Identification andGuiding Technological InterventionsRole: Co-Investigator (10% FTE)My work was to provide statistical expertise for this grant.
NIH U01AI068616 (PI: Fenton), 6/29/06 – 6/30/08Statistical and Data Management Center - International Maternal Pediatric Ado-lescent AIDS Clinical Trials GroupRole: Senior Statistician (50 ∼ 90% FTE)My work was to provide statistical expertise and leadership in the design, conduct,and analysis of clinical trials.
NIH R01AI051164 (PI: De Gruttola), 7/1/04 – 12/31/07Methods for Long-Term Follow-Up of HIV-Infected PatientsRole: Co-Investigator (25 ∼ 40% FTE)My work was to develop novel statistical methods for the study of HIV resistancemutations.
NIH U01AI041110 (PIs: Hughes, Fenton), 9/1/01 – 6/28/06Statistical and Data Management Center - Pediatric AIDS Clinical Trials GroupRole: Senior Statistician (45 ∼ 60% FTE)My work was to provide statistical expertise and leadership in the design, conduct,and analysis of clinical trials.
R37AI024643 (PI: Lagakos), 9/1/01 – 6/30/04Statistical Methods in AIDS ResearchRole: Co-Investigator (25% FTE)My work was to conduct research in statistical methodology.
This is a true and accurate statement of my activities and accomplishments. Iunderstand that misrepresentation in securing promotion and tenure may lead todismissal or suspension under ABOR Policy 6-201 J.1.b.

Source: http://publichealth.arizona.edu/sites/publichealth.arizona.edu/files/directory/cvs/CV_Hu.pdf